Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs 10X Genomics Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.84, while 10X Genomics Inc trades at $46.38 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | TXG | |
|---|---|---|
52-Week High | $112.91 | $45.80 |
52-Week Low | $106.96 | $11.34 |
Market Cap | — | $5.48B |
Sector | — | Health |
Enterprise Value | — | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $107.15, down 0.38% with a bearish technical signal from moving averages. Recent dividend payments include $0.42 in May 2026 and $0.41 in June 2026, reflecting steady income distribution. The fixed income ETF sector shows renewed investor interest amid economic resilience and rate uncertainty, as noted by ETF Trends on July 14, 2026.
Outlook remains cautious due to technical weakness and Federal Reserve policy risks. Opportunities exist for income-focused investors seeking corporate bond exposure, but rising rate expectations pose headwinds. Key risks include inflation persistence and narrowing market breadth impacting bond valuations.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
